NVO News

Novo Nordisk saw its stock drop 21% year-to-date, pressured by weaker-than-expected obesity drug trial results.

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL trial finds Rybelsus lowers cardiovascular risk by 14%.

Vivani Medical's NPM-139 semaglutide implant showed steady drug release and nearly 20% weight loss in preclinical studies, supporting long-term weight management.

Novo Nordisk secures global rights (excluding China) for UBT251 in a $2B+ deal with United Biotechnology, advancing obesity and diabetes treatment.

Novo Nordisk rejoined the ABPI after a two-year suspension linked to promotional concerns. Audits confirmed compliance with industry standards.

Novo Nordisk's REDEFINE 2 trial shows CagriSema led to significant weight loss in patients with obesity and type 2 diabetes. Regulatory filing is planned for 2026.

Pfizer has discontinued Beqvez for hemophilia B due to low patient demand and will focus on alternative treatments, including its approved therapy, Hympavzi.

Novo Nordisk sues KBP Biosciences, seeking $830 million in damages over Ocedurenone, alleging data misrepresentation that led to a failed Phase 3 trial.

Analysts at Intron Health, led by Naresh Chouhan, suggested that Friday's market reaction was excessively severe.

Novo Nordisk's stock is spiraling downwards, with technical analysis revealing a concerning picture of bearish momentum. Short-term opportunities may arise, but the broader downtrend remains strong.

Debate over tackling U.S. obesity epidemic sparks contrasting views from Trump's orbit: lifestyle changes vs. easier access to weight-loss drugs.

Novo Nordisk launches Wegovy in China to address rising obesity rates, priced lower than in the U.S. Initial sales start at a Shanghai public hospital.

Novo Nordisk's Q3 2024 report highlights a 21% YoY sales increase with strong gains in GLP-1 diabetes and obesity drugs but falls short of analyst expectations.

Regeneron reports Q3 EPS of $12.46, up 8% YoY, beating estimates. Revenue rose 11% to $3.72 billion. Key growth from Eylea, Libtayo, and Dupixent drives performance.

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will review Novo Nordisk's application for once-weekly insulin icodec on May 24. Concerns include an increased risk of hypoglycemia in type 1 diabetes patients.

Certain genes may predict strong responses to Novo Nordisk's Wegovy (semaglutide) in obesity treatment, with patients showing significant weight loss linked to a "hungry gut" genetic profile. This finding could enhance personalized obesity care, optimizing treatment outcomes.